NRX Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- For the 3rd quarter ended September 30th, 2026, NRx reported net patient revenue of $1.2 million compared with $0.2 million for the 3rd quarter of 2025.
- 3rd-quarter loss from operations was $8.1 million compared with $4 million from the prior quarter, while net loss was $2.2 million, or $0.05 per share, compared with $5.9 million, or $0.27 per share, for the prior comparable quarter.
- For the 9 months ended September 30th, 2026, net loss was $20.1 million versus $29 million in the comparable period of 2025, and loss from operations was $19.4 million versus $11.6 million.
- The company had approximately $19.8 million in cash and cash equivalents as of September 30th, 2026, compared with $7.8 million as of December 31st, 2025, and reported no convertible debt.
- NRx received FDA approval on October 29th, 2026, for its abbreviated new drug application for preservative-free ketamine, its first drug approval; the approval included a blow-fill-seal vial and Luer lock drug-device combination.
- The company said its 17-person sales force was in the field and it received its first order the day before the call.
- Hope Therapeutics operated 6 locations in Florida as of September 30th, 2026, and generated its first clinical revenue in Q4 2025.
- NRx Defense Systems received an $11.2 million initial prime contract from DARPA for the SPARC TMS clinical trial.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Third Quarter 2026 Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. Should you require any operator assistance, you may press star zero. I would now like to turn the conference over to Brian Korb of astr partners.
Please go ahead. Thank you, operator, and good morning, everyone.
Joining me on today's call are Dr. Jonathan Javitt, founder, chairman, and chief executive officer, and Michael Abrams, chief financial officer of NRx Pharmaceuticals. Following their prepared remarks, we will open the call for questions. Yesterday, NRx filed its quarterly report on Form 10-Q for the quarter ended September 30, 2026, with the Securities and Exchange Commission. The 10-Q is available on the investor section of the company's website and on the SEC's website. Before we begin, please note that statements made on this call that are not historical facts are forward-looking statements. Actual results may differ materially due to risks and uncertainties, including those described in the risk factor section of our most recent Form 10-K and subsequent filings with the SEC. I am now pleased to turn the call over to Dr. Jonathan Javitt, founder, chairman, and CEO of NRx Pharmaceuticals.
Jonathan, go ahead. Thank you, Brian.
Good morning, and thank you for attending our third quarter conference call. The third quarter of 2026 has been the quarter in which seeds that were planted two years ago have begun to grow into a sustainable orchard. As you recall, exactly two years ago, we announced the resignation of the company's former management and the board's recognition that we needed to chart a new path forward. The company at that time had no near-term path to an approved drug, was paralyzed by toxic debt, and lacked a strategic direction. Our market capitalization was $15 million, and the company reported $1.6 million in cash at the end of the quarter. Two years later, we have shed all the convertible debt from our balance sheet. We have attracted healthcare specialist institutional investors, led by the B Group, who have provided us with a path to profitability.
We've been granted our first FDA drug approval. We have a 17-person veteran sales force led by a seasoned commercial team, engaging customers every day, one of whom gave us our first order yesterday. Our market capitalization is approximately $95 million and has reached twice that in the past six months. We ended our third quarter with about $20 million in cash and cash equivalents. We have clinics that are generating revenue. We've earned the trust of the Defense Advanced Research Projects Agency, and we've been tasked with leading the clinical development of their most promising solution to treating depression and PTSD in the military.
We are gearing up for a commercially successful 2027, in which we aim to demonstrate a path to profitability, and we have an early-stage opportunity that may lead to the world's first disease-modifying drugs for ALS and schizophrenia, in partnership with the U.S. National Institutes of Health and the governments of France and Switzerland. A recurring theme that we hear from shareholders is the feeling that they've been diluted over the past two years as we've built a new, hopefully durable, and potentially near-term profitable company. In reality, management believes that the owners of approximately 11 million shares that were outstanding in September 2024 today own about 65% more value two years later, based on their proportionate share in our current enterprise. Over the same period, the S&P 500 increased half that amount, 31%.
While today's equity market is challenging for all biotechnology stocks, we hope that going forward, it will be less challenging for companies like ours that are actively booking revenue and earning profits than for companies that are still years away from a first drug approval. Over the two years since we changed our management team and became a working board building a working company, we've undergone extraordinary change in structure and focus. The quarterly report that we filed yesterday is far longer than usual, and we hope you will read the business description carefully to better understand who we have become. We anticipate that the business structure we've laid out will be the structure by which we operate NRx for the foreseeable future.
As outlined in the business description, we now have four divisions, each intended to be financed through mechanisms that are potentially non-dilutive to NRXP shareholders, and more importantly, each of which has near-term opportunity to become a profitable enterprise in its own right. We believe each of these has potential to return considerable value to those who own NRXP stock. In brief, those divisions are, one, our core NRx Pharmaceuticals company, which has expanded its focus from drugs that affect the central nervous system and depression and suicidality to encompass a promising sterile injectable products initiative. Two, our HOPE Therapeutics clinical division, in which we treat patients with those CNS conditions. Three, NRx Defense Systems, which just signed its first prime contract with the Department of War. And four, GeNeuro Incorporated, which has the potential to deliver the world's first disease-modifying drugs for ALS and schizophrenia.
NRx Pharmaceuticals was the original basis of, sorry, NeuroRx Pharmaceuticals was the original basis of NRx Pharmaceuticals, focused on the development of an innovative drug to treat bipolar depression, the drug we call NRX-101. NeuroRx has now expanded to encompass not only its foundation drug, but a new sterile injectable products division that has just been granted its first drug approval. The aim of NeuroRx sterile products is to deliver sterile injectable products at margins that are consistent with the margins for innovative drugs. A key focus of our plan was to concentrate on immediately revenue-generating drugs, such as preservative-free ketamine, that could provide a solid financial foundation to our company as we seek to bring even more valuable innovative drugs to the market. As you know, Chaim Hurvitz, former President of Teva International, is one of our founding investors and board members.
Chaim and I learned a great deal from his father, Eli Hurvitz, and later from Dr. Phil Frost, and the manner in which Teva built a solid foundation in immediately profitable generic drugs, and then supported the extraordinary success of COPAXONE and successor innovative drugs. When we founded the company, we did not set out to sell sterile injectable drugs. It was a byproduct of the FDA advising us in January 2023 that if we expected to use ketamine in conjunction with NRX-101, we would need to add psychiatry claims to generic ketamine. In working to satisfy that requirement, we discovered that the entire ketamine drug supply chain in the United States was broken. It had moved overseas, and Americans were threatened by chronic shortage of ketamine and other sterile injectable products.
We realized the critical need for sterile injectable drugs that could be manufactured in the United States at low cost and with minimal regulatory risk. We estimate the current United States demand for sterile injectable ketamine alone at approximately $400 million a year, and to be growing at more than 17% a year, as ketamine is increasingly used in hospitals for pain control as well as anesthesia. This estimate does not fully incorporate the potential of ketamine to be used in treatment of depression and PTSD under our NRX-100 program. If we add a few similar sterile products, NRx can double or triple its currently addressable market in early 2027. The entire U.S. generic sterile products market is estimated at $23 billion, according to IMARC. That is just generic drugs. It does not count the branded drugs.
Congressional and executive branch leaders have recognized the urgent national security need to bring the manufacture of strategic drugs back within the borders of the U.S. We are in active discussions with those leaders on both sides of the political aisle. In the post-COVID years, while nobody was looking, our sterile injectable supply chain became unstable to the point where 10%-20% of those drugs are now supplied by compounding pharmacies for lack of an FDA-approved drug. FDA is actually actively engaged in enforcement actions that highlight the risks of compounding, and our FDA is forcing many compounders out of business. Moreover, 503B compounded drugs may not be legally sold when an FDA-approved drug is available and not in drug shortage. This creates an urgent need and a growing opportunity for NRx's sterile injectable solutions. The real problem with these drugs is not the sterile drug, it is the glass bottle.
During our COVID experience with ZYESAMI, we learned that the cost of bottling a drug in glass is about $3.25 a unit. The cost is driven not only by the cost of the glass, but also by the relatively low volume and high labor intensity of a sterile glass bottling line. Ask yourself, when's the last time you saw a glass milk bottle in the grocery store, unless it was a boutique product? Until now, injectable drugs could not be manufactured in more economical blow-fill-seal packaging because there was no FDA-approved mechanism to transfer the medication from the BFS container to a sterile syringe in a manner that medication could be withdrawn from a glass vial.
We worked with our partner, Nephron Pharmaceuticals, and our German equipment manufacturer to solve that problem using a Luer lock drug device combination now approved as part of NRx's Abbreviated New Drug Application by the FDA on October 29, 2026, for preservative-free ketamine product. Although the Luer lock was previously incorporated in your grandfathered water for injection product, this was the first drug approval in which a blow-fill-seal vial was approved by FDA as a drug device combination. This innovation, which required hundreds of pages of regulatory documentation and engineering testing, will provide NRx with a market-leading platform for this and future sterile injectable drugs. Competitors will surely follow, but we predict it will take them considerable engineering time to stand up the manufacturing lines, and then years of stability testing to get to the point where they can compete with us in the market.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
